Gene · 5694
PSMB6: proteasome 20S subunit beta 6
12 sourcesgene-search-2026-11-11-0.2.0
Cite this record
ConductScience Library. PSMB6: proteasome 20S subunit beta 6. Genes, record 5694. Release gene-search-2026-11-11-0.2.0, 11 Nov 2026. https://conductscience.org/library/genes/5694
On this page
Gene
Proteins1
Reviewed human proteins whose Swiss-Prot entry states the gene.
| UniProt entry | Protein | Length | Structures | Gene stated in |
|---|---|---|---|---|
| P28072 | Proteasome subunit beta type-6 | 239 | 146 | Ensembl, GeneID, HGNC |
Source UniProt
Patents31
Patents whose sequence listing contains this protein's exact sequence. A patent can list a sequence without claiming it.
| Publication | Published | SEQ ID NO | Protein | Source |
|---|---|---|---|---|
| EP 4650780 A2 | 2025-11-19 | 2751 | P28072 | Espacenet |
| EP 4641202 A2 | 2025-10-29 | 4634 | P28072 | Espacenet |
| JP 2025517970 A | 2025-06-12 | 2751 | P28072 | Espacenet |
| KR 1020250017231 A | 2025-02-04 | 4634 | P28072 | Espacenet |
| US 11860162 B2 | 2024-01-02 | 1236 | P28072 | Espacenet |
| US 11564998 B2 | 2023-01-31 | 5007 | P28072 | Espacenet |
| US 11446398 B2 | 2022-09-20 | 67920 | P28072 | Espacenet |
| JP 2022524081 A | 2022-04-27 | 170891 | P28072 | Espacenet |
| US 11078247 B2 | 2021-08-03 | 9066 | P28072 | Espacenet |
| US 10746735 B2 | 2020-08-18 | 1236 | P28072 | Espacenet |
1 to 10 of 31
See all 31 patentsDrugs7
Drugs a ChEMBL mechanism record says act on the gene's protein, through Open Targets.
| Drug | ChEMBL ID | Mechanism | Action | Source |
|---|---|---|---|---|
| BORTEZOMIB | CHEMBL325041 | 26S proteasome inhibitor | INHIBITOR | ChEMBL |
| BORTEZOMIB D-MANNITOL | CHEMBL5315122 | 26S proteasome inhibitor | INHIBITOR | ChEMBL |
| CARFILZOMIB | CHEMBL451887 | 26S proteasome inhibitor | INHIBITOR | ChEMBL |
| IXAZOMIB | CHEMBL2141296 | 26S proteasome inhibitor | INHIBITOR | ChEMBL |
| IXAZOMIB CITRATE | CHEMBL3545432 | 26S proteasome inhibitor | INHIBITOR | ChEMBL |
| MARIZOMIB | CHEMBL371405 | 20S proteasome inhibitor | INHIBITOR | ChEMBL |
| OPROZOMIB | CHEMBL2103884 | 26S proteasome inhibitor | INHIBITOR | ChEMBL |
Trials1,241
Trials of those drugs. A trial joins the gene only through a drug that acts on it.
| Trial | Drug | Phase | Results first posted | Source |
|---|---|---|---|---|
| NCT07605416 | CARFILZOMIB | PHASE2 | ClinicalTrials.gov | |
| NCT07601100 | BORTEZOMIB | PHASE1/PHASE2 | ClinicalTrials.gov | |
| NCT07600151 | BORTEZOMIB | PHASE1/PHASE2 | ClinicalTrials.gov | |
| NCT07513129 | BORTEZOMIB | PHASE1 | ClinicalTrials.gov | |
| NCT07479979 | CARFILZOMIB | PHASE1/PHASE2 | ClinicalTrials.gov | |
| NCT07464210 | BORTEZOMIB | PHASE2 | ClinicalTrials.gov | |
| NCT07463807 | CARFILZOMIB | PHASE1/PHASE2 | ClinicalTrials.gov | |
| NCT07428369 | BORTEZOMIB | PHASE2/PHASE3 | ClinicalTrials.gov | |
| NCT07391657 | BORTEZOMIB | PHASE3 | ClinicalTrials.gov | |
| NCT07391657 | CARFILZOMIB | PHASE3 | ClinicalTrials.gov |
1 to 10 of 1,241
See all 1,241 trialsNIH grants473
NIH grants whose papers are about the gene, through NIH's grant-paper links.
| Grant | Title | PSMB6 papers | Newest fiscal year |
|---|---|---|---|
| R01AG011085 | Ubiquitin‐mediated proteolysis and cell cycle control | 7 | 2025 |
| P30CA044579 | University of Virginia Cancer Center Support Grant | 3 | 2025 |
| P50CA186781 | Mayo Clinic Multiple Myeloma SPORE | 3 | 2025 |
| P30AI027763 | UCSF-Bay Area Center for AIDS Research | 2 | 2025 |
| P30CA023108 | Cancer Center Support Grant | 2 | 2025 |
| P30CA030199 | Cancer Center Support Grant (CCSG) | 2 | 2025 |
| P50CA058223 | SPORE in Breast Cancer | 2 | 2025 |
| R01GM131641 | Mapping endogenous protein dynamics in living cells | 2 | 2025 |
| T32CA009109 | Cancer Research Training Program: From Molecular Mechanisms to Therapeutic Strategies | 2 | 2025 |
| T32ES018827 | Research Training in Environmental Toxicology | 2 | 2025 |
1 to 10 of 473Source NIH's project files
See all 473 nih grantsPapers696
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| An Investigation to Study Morphology, Nanomechanical Attributes, Transcriptomics, and Proteomics of Tumor Associated Macrophages Derived Extracellular Vesicles in the Tumor Microenvironment. | J Anal Oncol | 2026 | 42719843 | PubTator, text mining | PubMed |
| The pterocarpan (+)-PTC modulates cytoskeletal proteins and induces apoptosis in metastatic castration-resistant prostate cancer: a proteomic perspective. | Front Pharmacol | 2026 | 42318340 | PubTator, text mining | PubMed |
| Integrative Pan-Cancer Mapping of Proteasome Dependency Prioritizes PSMB5 and PSMB6 as Context-Dependent Vulnerability Biomarkers Linked to Immune Context. | Molecules | 2026 | 42280256 | PubTator, text mining | PubMed |
| Ubiquitination and degradation of CD47 enhances macrophage phagocytosis of hemolytic erythrocytes. | iScience | 2026 | 41568156 | PubTator, text mining | PubMed |
| Zinc-Related Proteasome Variants in Type 1 Diabetes: An in Silico-Guided Case-Control Study. | Metabolites | 2025 | 41441015 | PubTator, text mining | PubMed |
| Deep learning and multi-omics reveal programmed cell death-associated diagnostic signatures and prognostic biomarkers in gastric cancer. | Front Immunol | 2025 | 41293156 | PubTator, text mining | PubMed |
| [Protein biomarker screening and functional analysis of salivary exosomes in patients with ulcerative colitis]. | Beijing Da Xue Xue Bao Yi Xue Ban | 2025 | 41131760 | PubTator, text mining | PubMed |
| Predictive value of MHC-related genes in cervical cancer: implications for immunotherapy and prognostic nomogram development. | Discov Oncol | 2025 | 40888998 | PubTator, text mining | PubMed |
| Gene signatures associated with exosomes as diagnostic markers of postpartum depression and their role in immune infiltration. | Front Endocrinol (Lausanne) | 2025 | 40747300 | PubTator, text mining | PubMed |
| Proteasome caspase-like activity regulates stress granules and proteasome condensates. | Front Cell Dev Biol | 2025 | 40538982 | PubTator, text mining | PubMed |
1 to 10 of 696
See all 696 papersSources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this gene from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/genes/v1/5694
GET https://conductscience.org/api/genes/v1/5694/patents?page=2